Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Nanotheranostics

article

Christina K. Lee¹  Danielle F. Atibalentja¹  Lilian E. Yao¹  Jangho Park¹  Sibu Kuruvilla¹  Dean W. Felsher¹ 

[1] Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine;Division of Hematology, Department of Medicine, Stanford University School of Medicine

关键词: PD-L1;    PEG-PLGA;    MC38;    Immunotherapy;   

DOI  :  10.7150/ntno.65544

学科分类：大气科学

来源: Ivyspring International Publisher

【 摘 要 】

Background: Immune checkpoint therapies are effective in the treatment of a subset of patients in many different cancers. Immunotherapy offers limited efficacy in part because of rapid drug clearance and off-target associated toxicity. PEG-PLGA is a FDA approved, safe, biodegradable polymer with flexible size control. The delivery of immune checkpoint inhibitors such as anti-PD-L1 (α-PD-L1) via PEG-PLGA polymer has the potential to increase bioavailability and reduce immune clearance to enhance clinical efficacy and reduce toxicity.

【 授权许可】

CC BY-NC